## **ICMJE DISCLOSURE FORM**

Date:		5/28/2023	5/28/2023			
Your Name:		Prof.dr. C.J	Prof.dr. C.J. van der Laken			
Manuscript Title:		Reumatiscl	Reumatische klachten door immunotherapie bij kanker: Van de regen in de drup.			
Manuscript Number (if known):		own):D7698	D7698			
con affe indi	tent of your manuscrip cted by the content of cate a bias. If you are author's relationships,	. "Related" means the manuscript. Distinct doubt about whet activities/interests ion, you should dec	e ask you to disclose all relationships/activities/interests listed below that are related to the sted" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily about whether to list a relationship/activity/interest, it is preferable that you do so.  es/interests should be defined broadly. For example, if your manuscript pertains to the ushould declare all relationships with manufacturers of antihypertensive medication, even if in the manuscript.			
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.				ithout time limit. For all other items, the time		
			th whom you have this ate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time	frame: Since the initial planning	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	□ <b>None</b> Case collection, medial final draft	dical writing, article review up	Click the tab key to add additional rows.		
			Time frame: past 36 month	s		
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None				
3	Royalties or licenses	⊠ None				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	GSK, Lilly	Payments to institute
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Lilly, Novartis, Abbvie, Pfizer, UCB Pharma, Galapagos	Payments mostly to institute, travel reimbursement to myself
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[□] None	
8	Patents planned, issued or pending	[⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Board member IRON working group NVR (Dutch Rheumatology Association), OMERACT member (international working group) for development clinical criteria of immunotherapy related rheumatogical side effects, program leader inflammatory diseases in Amsterdam Research Institute of Infection & Immunity.	

11	Stock or stock options	Name all entities with whom you have this relationship or indicate none (add rows as needed)  [  None	Specifications/Comments (e.g., if payments were made to you or to your institution)		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None			
13	Other financial or non-financial interests	[⊠] None			
Please place an "X" next to the following statement to indicate your agreement:     I certify that I have answered every question and have not altered the wording of any of the questions on this form.					